Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NV › Las Vegas › NPI 1043256886
Lab

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated was paid $59.32M by Medicaid between Jan 2018 and Dec 2024, across 544 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS INCORPORATED
LAS VEGAS, NV 89119
33aNPI1043256886assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$59.32M
24GClaims13,415,550
24DCodes billed544
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Nevada

Rank by total paid#1 of 31
Median peer was paid$269K
This provider vs. median221×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$500K$1.0M$1.5M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,847,181$6.22M
20191,863,845$5.85M
20201,805,620$8.37M
20212,166,875$11.18M
20221,951,046$11.01M
20231,960,954$9.11M
2024incomplete1,820,029$7.57M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 15% 134,414 118,594 $8.95M
80050 General health panel 4.7% 345,936 335,883 $2.77M
80061 Lipid panel 4.1% 792,596 759,895 $2.40M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.8% 328,844 313,180 $2.24M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 3.8% 279,200 254,106 $2.23M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 3.7% 279,689 254,619 $2.18M
80053 Comprehensive metabolic panel 3.3% 778,225 703,229 $1.97M
84443 Thyroid stimulating hormone (TSH) 3.0% 418,186 401,360 $1.77M
86003 2.9% 54,905 49,474 $1.72M
83036 Hemoglobin; glycosylated (A1C) 2.4% 684,159 654,506 $1.42M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.4% 110,309 102,325 $1.40M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.2% 651,855 577,598 $1.29M
532 more codes
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2.1% 38,527 $1.27M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 1.6% 10,026 $928K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.5% 138,369 $863K
80074 1.3% 62,374 $751K
86480 1.2% 44,925 $725K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.2% 95,391 $706K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.2% 101,528 $700K
82607 1.0% 171,703 $614K
84439 1.0% 322,743 $613K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 30,434 $583K
80081 <1% 38,496 $576K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 91,671 $518K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 58,889 $511K
87086 Culture, bacterial; quantitative colony count, urine <1% 259,745 $469K
84481 <1% 100,933 $440K
83970 <1% 49,758 $434K
82728 <1% 151,166 $429K
84403 <1% 65,577 $427K
83013 <1% 27,632 $404K
82746 <1% 118,655 $400K
86235 <1% 27,079 $394K
87536 <1% 19,544 $378K
87799 <1% 22,219 $371K
87088 <1% 204,008 $367K
86803 <1% 101,970 $357K
84153 <1% 78,400 $305K
82652 <1% 38,136 $282K
86769 <1% 7,723 $271K
85027 <1% 176,402 $265K
81001 <1% 352,973 $259K
86696 <1% 45,271 $252K
82670 <1% 33,966 $240K
83550 <1% 143,447 $239K
36415 Collection of venous blood by venipuncture <1% 351,491 $233K
81513 <1% 18,093 $222K
83001 <1% 46,377 $209K
83540 <1% 155,577 $208K
84402 <1% 34,573 $206K
87902 <1% 3,128 $200K
88185 <1% 878 $199K
86038 <1% 69,531 $196K
82570 <1% 195,342 $189K
86360 <1% 16,196 $188K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 2,504 $187K
84702 <1% 61,378 $187K
87522 Neg quan hep c or qual rna <1% 16,907 $186K
83002 <1% 38,956 $173K
82043 <1% 162,317 $173K
86592 <1% 159,224 $172K
82785 <1% 44,278 $171K
87340 <1% 71,140 $170K
87070 <1% 75,212 $166K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 2,159 $160K
86695 <1% 42,238 $160K
83525 <1% 62,776 $160K
84146 <1% 32,079 $153K
86376 <1% 43,660 $150K
87186 <1% 70,399 $146K
87077 <1% 70,944 $142K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 3,669 $131K
88142 <1% 48,926 $131K
86140 <1% 106,337 $128K
84144 <1% 24,290 $124K
83735 <1% 83,163 $124K
84550 <1% 115,824 $120K
87512 <1% 9,174 $119K
80048 Basic metabolic panel (calcium, ionized) <1% 62,638 $118K
82105 <1% 26,910 $116K
86359 <1% 9,735 $108K
87081 <1% 71,624 $102K
83655 <1% 29,881 $99K
86706 <1% 44,482 $98K
84436 <1% 59,320 $98K
84270 <1% 17,009 $93K
82784 <1% 28,422 $93K
83520 <1% 19,951 $92K
83880 <1% 12,921 $92K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 10,791 $89K
82248 <1% 65,319 $89K
80069 <1% 46,901 $89K
86800 <1% 27,712 $87K
87660 <1% 30,343 $85K
86704 <1% 38,349 $84K
86008 <1% 7,739 $84K
86708 <1% 35,845 $83K
82627 <1% 15,181 $82K
86147 <1% 5,272 $82K
87480 <1% 30,347 $82K
87510 <1% 30,313 $81K
85652 <1% 124,143 $77K
84445 <1% 7,148 $77K
86160 <1% 15,237 $75K
85610 <1% 83,356 $73K
82672 <1% 12,647 $73K
86225 <1% 26,061 $72K
84681 <1% 14,954 $71K
82378 <1% 16,034 $70K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 3,668 $69K
85730 <1% 49,798 $67K
83516 <1% 18,501 $67K
86200 <1% 23,441 $66K
86780 <1% 19,461 $65K
87209 <1% 15,443 $64K
80076 <1% 35,566 $61K
88141 <1% 12,275 $61K
84154 <1% 16,387 $61K
82024 <1% 6,830 $60K
82977 <1% 31,118 $59K
82677 <1% 7,117 $58K
86431 <1% 41,587 $58K
87901 <1% 1,046 $58K
83615 <1% 43,369 $56K
86146 <1% 3,787 $56K
86039 <1% 22,036 $55K
86355 <1% 4,846 $55K
82550 <1% 37,029 $54K
84100 <1% 48,160 $53K
84207 <1% 8,218 $53K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 1,369 $52K
86357 <1% 4,457 $52K
82533 <1% 13,601 $50K
82274 <1% 14,442 $49K
80164 <1% 9,970 $46K
87497 <1% 3,404 $46K
86300 <1% 11,968 $45K
84479 <1% 31,299 $43K
84425 <1% 9,477 $42K
83690 <1% 27,356 $42K
84480 <1% 17,469 $39K
87147 <1% 28,918 $38K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 569 $38K
86336 <1% 7,267 $36K
86141 <1% 11,908 $35K
80197 <1% 8,742 $34K
82107 <1% 3,309 $33K
84156 <1% 42,402 $33K
84134 <1% 9,457 $32K
86334 <1% 8,016 $32K
82150 <1% 21,737 $32K
82565 <1% 30,713 $31K
87177 <1% 15,380 $31K
82951 <1% 11,458 $31K
82950 <1% 30,751 $31K
83090 <1% 9,965 $30K
86255 <1% 8,521 $30K
86162 <1% 5,392 $30K
83014 <1% 17,480 $30K
86304 <1% 5,912 $29K
84165 <1% 12,534 $29K
87900 <1% 1,046 $29K
86787 <1% 10,205 $28K
87517 <1% 3,310 $28K
84703 <1% 15,838 $26K
81003 <1% 53,301 $26K
84305 <1% 4,475 $26K
87563 <1% 3,883 $26K
82247 <1% 19,092 $25K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,087 $25K
83993 <1% 5,084 $25K
80202 <1% 7,705 $24K
99199 Unlisted special service, procedure or report <1% 31,999 $24K
87631 <1% 4,004 $23K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 1,470 $23K
82088 <1% 2,797 $23K
80177 <1% 5,599 $23K
83498 <1% 3,704 $23K
87449 <1% 7,450 $22K
87529 <1% 2,813 $22K
87427 <1% 6,997 $21K
86665 <1% 2,959 $21K
82140 <1% 5,631 $21K
84520 <1% 24,352 $21K
87338 <1% 6,964 $20K
82330 <1% 7,386 $19K
85246 <1% 3,566 $19K
86364 <1% 7,517 $19K
83020 <1% 5,574 $19K
86317 <1% 5,319 $18K
85379 <1% 7,665 $18K
83921 <1% 5,797 $17K
87045 <1% 7,392 $17K
85245 <1% 3,221 $17K
86593 <1% 14,404 $17K
84432 <1% 6,019 $17K
86762 <1% 5,086 $16K
84466 <1% 5,224 $16K
85240 <1% 3,900 $16K
86021 <1% 5,008 $15K
87205 <1% 20,998 $15K
84460 <1% 16,237 $15K
86870 <1% 1,755 $15K
83519 <1% 4,659 $15K
86341 <1% 2,350 $15K
86635 <1% 2,850 $15K
87493 <1% 2,204 $14K
88312 <1% 862 $14K
87324 <1% 4,792 $14K
88184 <1% 855 $13K
86705 <1% 5,041 $13K
87075 <1% 5,580 $13K
86301 <1% 2,566 $13K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 2,185 $13K
87329 <1% 5,059 $12K
86381 <1% 2,355 $12K
84450 <1% 10,939 $12K
85247 <1% 2,442 $12K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 3,115 $12K
82542 <1% 2,887 $12K
83021 <1% 4,004 $12K
86812 <1% 2,553 $11K
85045 <1% 18,109 $11K
84478 <1% 11,082 $11K
87535 <1% 1,734 $11K
86850 <1% 6,277 $11K
82390 <1% 4,130 $11K
88230 <1% 370 $10K
81596 <1% 3,408 $10K
87040 <1% 4,795 $10K
80175 <1% 2,451 $10K
83721 <1% 7,615 $10K
83521 <1% 2,170 $10K
82947 <1% 11,087 $10K
83883 <1% 2,682 $10K
82731 <1% 752 $10K
88262 <1% 301 $10K
87046 <1% 4,537 $9K
82310 <1% 13,099 $9K
82397 <1% 2,062 $9K
84446 <1% 2,207 $9K
82172 <1% 3,963 $9K
85613 <1% 4,303 $9K
87102 <1% 11,709 $9K
82103 <1% 2,442 $9K
86361 <1% 2,546 $9K
87625 <1% 2,392 $8K
82747 <1% 1,931 $8K
84244 <1% 2,080 $8K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 487 $8K
84630 <1% 3,237 $8K
82668 <1% 1,923 $8K
87206 <1% 4,408 $8K
80178 <1% 3,511 $8K
82040 <1% 7,633 $8K
86664 <1% 2,377 $7K
86709 <1% 2,550 $7K
84590 <1% 2,353 $7K
87150 <1% 976 $7K
81025 <1% 4,186 $7K
82232 <1% 2,779 $7K
80299 <1% 1,736 $7K
85306 <1% 1,979 $7K
86901 <1% 10,039 $7K
86900 <1% 9,992 $7K
85018 <1% 13,375 $7K
86777 <1% 1,858 $6K
83010 <1% 2,395 $6K
87634 <1% 346 $6K
82164 <1% 2,139 $6K
86606 <1% 990 $6K
85014 <1% 11,946 $6K
82085 <1% 2,861 $6K
80051 <1% 7,705 $6K
84166 <1% 2,141 $6K
82653 <1% 1,368 $6K
80183 <1% 1,320 $6K
83704 <1% 1,636 $6K
82525 <1% 1,883 $6K
87106 <1% 4,078 $6K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 228 $6K
86015 <1% 2,620 $6K
86337 <1% 790 $5K
87255 <1% 1,234 $5K
80156 <1% 1,267 $5K
87116 <1% 2,137 $5K
84155 <1% 7,270 $5K
82157 <1% 916 $5K
84482 <1% 1,370 $5K
82985 <1% 1,866 $5K
86698 <1% 887 $5K
84132 <1% 4,896 $5K
85303 <1% 1,838 $5K
81229 <1% 578 $5K
82465 <1% 8,472 $5K
86036 <1% 1,953 $5K
86335 <1% 1,080 $5K
81015 <1% 4,844 $5K
88342 <1% 595 $5K
86765 <1% 1,824 $5K
82681 <1% 949 $4K
86735 <1% 1,777 $4K
82952 <1% 5,241 $4K
82626 <1% 1,007 $4K
84484 <1% 2,242 $4K
86618 <1% 1,214 $4K
84075 <1% 3,948 $4K
84238 <1% 579 $4K
86702 <1% 2,069 $4K
82530 <1% 1,310 $4K
84252 <1% 844 $4K
80180 <1% 589 $4K
80159 <1% 646 $4K
86644 <1% 1,287 $4K
85660 <1% 3,054 $4K
83695 <1% 2,295 $3K
87101 <1% 1,564 $3K
80185 <1% 951 $3K
86645 <1% 929 $3K
85041 <1% 6,264 $3K
87184 <1% 849 $3K
85384 <1% 1,445 $3K
87015 <1% 2,098 $3K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 1,058 $3K
88304 <1% 575 $3K
86617 <1% 322 $3K
83698 <1% 762 $3K
86701 <1% 2,072 $3K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 1,617 $3K
80235 <1% 374 $3K
84295 <1% 2,115 $3K
82175 <1% 500 $3K
82104 <1% 791 $2K
85060 <1% 353 $2K
81241 <1% 1,206 $2K
85300 <1% 1,017 $2K
86880 <1% 1,852 $2K
85049 <1% 2,598 $2K
88112 <1% 522 $2K
83835 <1% 884 $2K
83825 <1% 565 $2K
86060 <1% 1,258 $2K
87481 <1% 976 $2K
83527 <1% 899 $2K
88173 <1% 286 $2K
84300 <1% 1,873 $2K
87807 <1% 808 $2K
82679 <1% 396 $2K
80055 <1% 262 $2K
80201 <1% 452 $2K
86316 <1% 586 $2K
83935 <1% 1,239 $2K
85048 <1% 3,521 $2K
84591 <1% 1,712 $2K
85007 <1% 2,901 $2K
82340 <1% 1,123 $2K
86308 <1% 1,596 $2K
89055 <1% 2,098 $2K
82435 <1% 1,246 $2K
86258 <1% 496 $2K
87107 <1% 449 $2K
80184 <1% 392 $1K
83930 <1% 1,003 $1K
85004 <1% 1,945 $1K
89050 <1% 1,565 $1K
81479 Unlisted molecular pathology procedure <1% 296 $1K
86612 <1% 343 $1K
82610 <1% 300 $1K
83003 <1% 323 $1K
87425 <1% 365 $1K
87076 <1% 508 $1K
87220 <1% 1,100 $1K
84597 <1% 299 $1K
81243 <1% 473 $1K
87632 <1% 81 $1K
81206 <1% 582 $1K
86001 <1% 160 $984.49
81240 <1% 633 $978.88
81270 <1% 297 $968.21
87350 <1% 354 $943.37
84157 <1% 1,176 $924.01
82553 <1% 375 $921.91
82166 <1% 295 $921.54
84080 <1% 563 $892.58
86886 <1% 555 $868.53
82507 <1% 136 $856.44
83986 <1% 953 $831.04
85305 <1% 386 $828.60
88237 <1% 58 $824.60
88341 <1% 199 $810.15
85598 <1% 208 $791.97
82787 <1% 167 $782.96
89051 <1% 693 $781.99
85597 <1% 272 $777.38
84182 <1% 39 $772.31
82945 <1% 875 $766.86
86148 <1% 977 $736.38
86041 <1% 190 $732.24
84145 <1% 109 $722.52
85301 <1% 490 $699.21
82575 <1% 327 $686.53
85302 <1% 264 $651.91
87906 <1% 40 $612.11
80503 <1% 106 $574.88
36416 <1% 4,306 $558.51
84133 <1% 512 $535.37
82642 <1% 243 $510.96
83718 <1% 361 $510.30
88264 <1% 58 $510.12
86778 <1% 187 $498.74
82374 <1% 408 $467.13
86596 <1% 83 $466.93
86256 <1% 161 $462.23
87254 <1% 116 $457.20
80203 <1% 95 $449.12
82656 <1% 150 $443.90
87521 Neg quan hep c or qual rna <1% 39 $430.48
83951 <1% 52 $419.60
82239 <1% 120 $389.71
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 213 $379.04
83916 <1% 82 $375.74
80158 <1% 104 $369.58
83945 <1% 122 $352.55
84560 <1% 314 $341.06
86671 <1% 157 $326.27
87109 <1% 105 $317.12
82180 <1% 132 $316.23
80162 <1% 183 $304.43
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 2,879 $296.96
82365 <1% 71 $288.76
81511 <1% 5,326 $287.92
86231 <1% 130 $267.82
83630 <1% 43 $261.99
86774 <1% 93 $261.37
83605 <1% 162 $259.23
86037 <1% 120 $249.81
82042 <1% 240 $249.13
88271 <1% 12 $248.37
88361 <1% 15 $238.15
86631 <1% 43 $222.53
84105 <1% 202 $217.35
86707 <1% 61 $213.00
82955 <1% 280 $199.38
86609 <1% 48 $184.59
84140 <1% 51 $181.10
87328 <1% 54 $180.65
86628 <1% 25 $171.03
82671 <1% 39 $168.16
86632 <1% 71 $166.41
82657 <1% 80 $149.70
81256 <1% 288 $140.56
83873 <1% 32 $137.07
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 27 $130.49
86356 <1% 17 $129.22
86403 <1% 31 $124.69
84255 <1% 13 $121.94
82308 <1% 16 $120.47
84163 <1% 165 $116.75
82705 <1% 181 $110.56
88307 <1% 13 $107.72
84206 <1% 31 $107.32
82384 <1% 29 $102.12
81279 <1% 72 $99.08
81339 <1% 45 $99.08
80195 <1% 12 $82.35
84392 <1% 64 $77.76
84260 <1% 12 $77.12
85307 <1% 24 $76.93
86043 <1% 33 $74.05
81291 <1% 409 $56.28
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 1,540 $53.81
81374 <1% 270 $48.31
86648 <1% 28 $48.12
86366 <1% 20 $46.80
89060 <1% 41 $46.11
87140 <1% 45 $45.91
83992 <1% 6,028 $36.69
82595 <1% 24 $36.31
80365 <1% 30,564 $28.42
80361 <1% 34,173 $28.42
86340 <1% 14 $27.40
99001 <1% 38,843 $23.07
84433 <1% 27 $22.91
84376 <1% 12 $20.97
80324 <1% 4,263 $14.10
81512 <1% 534 $13.90
84143 <1% 13 $13.56
88302 <1% 31 $12.10
80368 <1% 5,489 $11.61
88300 <1% 61 $10.60
80500 <1% 72 $10.45
80369 <1% 1,516 $9.86
80165 <1% 95 $7.86
80374 <1% 2,277 $1.87
80340 0% 4,494 $0.00
80367 0% 4,513 $0.00
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) 0% 315 $0.00
80320 0% 5,164 $0.00
80359 0% 6,303 $0.00
80353 0% 6,065 $0.00
80345 0% 7,208 $0.00
80333 0% 4,494 $0.00
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision 0% 428 $0.00
80358 0% 8,093 $0.00
80330 0% 4,495 $0.00
80349 0% 22,625 $0.00
80357 0% 4,497 $0.00
87503 0% 30 $0.00
80363 0% 258 $0.00
80329 0% 274 $0.00
87506 0% 37 $0.00
81508 0% 71 $0.00
89320 0% 12 $0.00
86905 0% 12 $0.00
80326 0% 5,050 $0.00
80372 0% 5,170 $0.00
80337 0% 5,050 $0.00
80348 0% 7,922 $0.00
80370 0% 5,047 $0.00
80364 0% 4,518 $0.00
80360 0% 4,816 $0.00
80321 0% 8,119 $0.00
80338 0% 5,050 $0.00
80344 0% 4,494 $0.00
80377 0% 5,050 $0.00
80339 0% 226 $0.00
80366 0% 5,887 $0.00
80362 0% 1,004 $0.00
80346 0% 12,556 $0.00
80356 0% 7,468 $0.00
80373 0% 12,497 $0.00
80354 0% 7,639 $0.00
81257 0% 230 $0.00
80342 0% 240 $0.00
80355 0% 4,948 $0.00
80323 0% 6,186 $0.00
80332 0% 227 $0.00
81219 0% 55 $0.00
87999 0% 266 $0.00
0001M 0% 15 $0.00
89321 0% 12 $0.00
81403 0% 43 $0.00
81381 0% 51 $0.00
87538 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.